Anzeige
Mehr »
Login
Donnerstag, 23.01.2025 Börsentäglich über 12.000 News von 682 internationalen Medien
Micro Cap & Branchenriese: Heute rein? - Partnerschaft entfacht Übernahmefantasien!
Anzeige

Indizes

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Aktien

Kurs

%
News
24 h / 7 T
Aufrufe
7 Tage

Xetra-Orderbuch

Fonds

Kurs

%

Devisen

Kurs

%

Rohstoffe

Kurs

%

Themen

Kurs

%

Erweiterte Suche
PR Newswire
429 Leser
Artikel bewerten:
(2)

Prabha Khaitan Foundation: Kitaab Festival draws Indian booklovers

Finanznachrichten News

NEW DELHI, Jan. 4, 2022 /PRNewswire/ -- It was an evening of history lessons and lively discussions as senior journalist Anshul Chaturvedi's debut historical fiction novel, 'A Bird From Afar', was recently launched at the Kitaab Festival in Delhi organised by Prabha Khaitan Foundation and presented by Shree Cement.

Prabha Khaitan Foundation Logo

The book, Chaturvedi's fourth, is a fictional narrative set in World War 2. It explores the journey of the Free India Legion raised in wartime Germany by Indian nationalist leader Subhas Chandra Bose in 1942, after Stalingrad and the North African theatre fall to the Axis. Bose, a widely revered leader in India, sometimes scrutinized sharply abroad for taking the assistance of the Axis in his efforts to liberate India from British rule, is the principal character of the novel.

"Subhas Bose is many things to many people, but, to me, he is someone I empathize with, am almost fond of. I cannot find easy, obvious or universally acceptable choices coming his way. And I admire how he faced the endless dilemmas life sent his way, without, at any point, being a man of compromise or adjustment. And I admire even more how, instead of being nothing more than a man of steel forged by all those fires, he retained and sustained his sensitivity, inclusiveness and objectivity. I have often mulled over the "if this had been" aspects of his life. I searched for some such stories to read, like Robert Harris's 'Fatherland', in the Indian context. I could not find much, perhaps because there is in any case so much mystery, intrigue and speculation about his real life. And then, I ended up writing the book that I wanted to read," Chaturvedi said at the launch, explaining the journey of the book.

He added, "With much trepidation, I requested Mihir Bose, who has written a very good biography of Subhas indeed, 'The Lost Hero', to read and hopefully say a couple of non-critical lines about the book in advance. He sent back a note that ended with this - 'He combines a sure grasp of history with an ability to convert little-known facts into a marvellous fictional page-turner, establishing himself as the Robert Harris of India.' And I felt I could now happily retire from fiction writing, even before the launch!"

Speaking about the book, senior bureaucrat and CEO of the Niti Aayog, India's primary policy planning body, Amitabh Kant, said, "It is a tremendous reading. He (Chaturvedi) deals with the subject with a lot of compassion. Imagine the ethical dilemmas that Bose was undergoing; he wanted to free India and so had to work with the Nazis. The book brings out Bose's character, uniqueness and commitment to the freedom of India. It's one of the finest books I have read in recent times."

Global marketing maven Suhel Seth and award-winning Indian filmmaker Nila Madhab Panda were present at the launch. The book, published by Pan Macmillan India, is available on Amazon.com and at leading bookstores.

Logo: https://mma.prnewswire.com/media/1572874/Prabha_Khaitan_Foundation_Logo.jpg
Logo: https://mma.prnewswire.com/media/1719565/Kitaab_Festival_Logo.jpg
Photo: https://mma.prnewswire.com/media/1719566/Anshul_Chaturvedi.jpg

Kitaab Festival Logo
Author Anshul Chaturvedi at Kitaab Festival

© 2022 PR Newswire
Gewinner im Megamarkt
Biotechnologie ist eine der bedeutendsten Zukunftstechnologien unserer Zeit. Zahlreiche Biotechnologie- und Pharmakonzerne haben sich unter anderem dem Kampf gegen Tumorerkrankungen verschrieben. Der weltweite Markt für Krebsmedikamente verzeichnet ein stetiges Wachstum. Für das Jahr 2025 wird ein Umsatz von etwa 190,3 Milliarden Euro prognostiziert, mit einer erwarteten jährlichen Wachstumsrate von 6,42% bis 2029, was zu einem geschätzten Marktvolumen von 244,1 Milliarden Euro führen würde.

Wir haben 3 aussichtsreiche Biotechnologieaktien mit Schwerpunkt Erforschung und Entwicklung von Wirkstoffen gegen Tumorerkrankungen ausfindig gemacht, die in den kommenden Monaten und Jahren erhebliches Aufwärtspotenzial versprechen und Vervielfachungspotenzial besitzen.

Fordern Sie jetzt unseren neuen kostenlosen Spezialreport an und erfahren Sie, welche 3 Biotech-Aktien durchstarten und zu Ihrem Börsenerfolg in 2025 beitragen könnten!
Werbehinweise: Die Billigung des Basisprospekts durch die BaFin ist nicht als ihre Befürwortung der angebotenen Wertpapiere zu verstehen. Wir empfehlen Interessenten und potenziellen Anlegern den Basisprospekt und die Endgültigen Bedingungen zu lesen, bevor sie eine Anlageentscheidung treffen, um sich möglichst umfassend zu informieren, insbesondere über die potenziellen Risiken und Chancen des Wertpapiers. Sie sind im Begriff, ein Produkt zu erwerben, das nicht einfach ist und schwer zu verstehen sein kann.